Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 14/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1017858 | 0.86 | KMT2A (0.52) | KMT2ASIGMAR1KDM1ACCR3 | |
| SCHEMBL1019239 | 0.85 | KMT2A (0.58) | CHRM3KMT2ASIGMAR1CCR3 | |
| SCHEMBL12955010 | 0.80 | USP30 (0.48) | KMT2ASIGMAR1KDM1ACCR3 | |
| SCHEMBL1019474 | 0.78 | KDM1A (0.56) | KMT2ASIGMAR1KDM1A | |
| SCHEMBL28744419 | 0.78 | CYP2D6 (0.73) | CHRM3KMT2ASIGMAR1KDM1A | |
| SCHEMBL1020330 | 0.78 | MEN1 (0.47) | CHRM3KMT2AKDM1ACCR3 | |
| SCHEMBL31310223 | 0.77 | KDM1A (0.55) | KMT2ASIGMAR1KDM1A | |
| SCHEMBL12438436 | 0.77 | CYP2D6 (0.71) | CHRM3SIGMAR1KDM1A | |
| SCHEMBL1017905 | 0.75 | CHRM3 (0.61) | CHRM3PRMT5 | |
| SCHEMBL1020291 | 0.75 | CHRM3 (0.61) | CHRM3PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101848899-B | As the N-benzyl of LXR conditioning agent, N '-aryl carbonyl bridged piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2016-03-02 | — | — | CN | disclosed |
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | disclosed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | disclosed |
| CN-101848899-A | N-benzyl, n' -arylcarbonylpiperazine derivatives as lxr modulators | ORGANON NV | 2010-09-29 | — | — | CN | disclosed |
| EP-2190827-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. Organon (NL) | 2010-06-02 | — | — | EP | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | NPC1L1, NPC1, ABCB11 | CHRM3 3452/4885KMT2A 4268/4885SIGMAR1 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.